Medicine

Abbott Receives FDA Approval for TriClip, a Medical Device for Repairing Tricuspid Regurgitation

April 4, 2024April 4, 2024 admin

Approval comes amid positive results from TRILUMINATE trial, which demonstrated improvement in 90% of participants treated for a leaky tricuspid heart valve.

Related Posts

Global Launch Strategies in the Current Political Climate

FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk

Navigating Distrust: Pharma in the Age of Social Media

Leave a Reply Cancel reply